Arthritis & Rheumatology
Audio Summaries

Identification of Novel Non-coding Genetic Variants of Serum Urate Using Whole Genome Sequencing in 7,339 Chinese

Mar 24, 2026

The authors aimed to investigate the genetic architecture of low-frequency and rare variants associated with serum urate (SU) levels in East Asian populations, specifically focusing on their implications for gout and cardiometabolic diseases. Through whole-genome sequencing of 7,339 Han Chinese participants, they identified novel male-specific loci and rare variants that may influence SU regulation, enhancing understanding of the genetic factors contributing to SU levels and potential targets for precision therapies.

Subsets of Lupus Patients Identified by Gene Expression Profiles Exhibit Differential Clinical Responsiveness to Baricitinib

Mar 23, 2026

The authors aimed to identify subsets of systemic lupus erythematosus (SLE) patients that exhibit differential clinical responsiveness to baricitinib, a JAK1 inhibitor. Through transcriptomic analysis of 272 patients, they identified eight molecular endotypes, with significant clinical responses to baricitinib observed in endotypes D and G. The study highlights that treatment-responsive subsets were not identifiable through clinical features alone, emphasizing the importance of gene expression profiles in predicting therapeutic outcomes.

Validation of International Classification of Diseases (ICD) code-based case definitions of immune checkpoint inhibitor associated inflammatory arthritis from administrative health data

Mar 23, 2026

The authors aimed to validate International Classification of Diseases (ICD) code-based case definitions for immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA) using administrative health data. Their study found that the best-performing case definition, which included at least one ICD code for inflammatory arthritis, achieved a sensitivity of 88% and specificity of 86.7%, indicating that these definitions can effectively support ICI-IA surveillance and research.

Functional Impact of Structural Damage in Psoriatic Arthritis: Insights from a Prospective Cohort Study

Mar 19, 2026

The authors aimed to investigate the relationship between radiographic structural damage and physical function (PF) in patients with psoriatic arthritis (PsA). Their findings indicate that greater structural damage, especially severe joint destruction, is significantly associated with poorer PF outcomes, underscoring the need for early detection and intervention to prevent joint damage in this population.

A Rare RIPK3 Variant Enhances Necroptosis and Promotes Inflammation in a Still's Disease-like Autoinflammatory Syndrome

Mar 19, 2026

This study investigates the genetic basis of a familial Still's disease-like autoinflammatory syndrome, identifying a novel heterozygous RIPK3 p.Q134K variant that enhances necroptosis and inflammation. The authors demonstrate that this variant leads to increased RIPK3 kinase activity and promotes pro-inflammatory signaling pathways, establishing aberrant RIPK3 activation as a key driver of autoinflammation. These findings expand the understanding of RIPK3-associated diseases and their role in systemic autoinflammatory conditions.

Association of Clonal Hematopoiesis with Incident, Late-Onset, Seropositive Rheumatoid Arthritis

Mar 18, 2026

The authors aimed to investigate the association between clonal hematopoiesis (CH) and the risk of developing late-onset, seropositive rheumatoid arthritis (RA). Their findings indicate that CH, particularly DNMT3A-mutated CHIP and certain chromosomal alterations, significantly increase the risk of incident seropositive RA, while no such association was observed for seronegative RA. Additionally, genetically predicted higher levels of complement proteins appeared to modify this association, suggesting a complex interplay between genetic factors and RA susceptibility.

Coverage generosity of novel anti-rheumatic drugs in Medicare Advantage and stand-alone Part D plans

Mar 17, 2026

The authors aimed to evaluate the coverage of self-administered disease-modifying anti-rheumatic drugs (DMARDs) in Medicare Part D plans from 2022 to 2026. They found that while coverage was high for some TNF inhibitors and a JAK inhibitor, significant gaps existed for other DMARDs, particularly abatacept, with only a small percentage of plans covering all drug classes. This variability in coverage highlights potential barriers to accessing effective rheumatoid arthritis treatments, necessitating further research on the implications of these formulary exclusions.

Telocyte Deletion is Associated with Loss of Lymphatic Drainage and Exacerbation of Inflammatory-Erosive Arthritis in Mice

Mar 16, 2026

The authors investigate the role of telocytes in lymphatic drainage and inflammatory-erosive arthritis using transgenic mice models. They find that the depletion of telocytes leads to impaired lymphatic function and worsens joint pathology in zymosan-induced arthritis, suggesting that telocytes are crucial for maintaining synovial lymphatic system integrity and may serve as potential therapeutic targets for rheumatoid arthritis.

Immune checkpoint inhibitor-associated inflammatory arthritis

Mar 9, 2026

The authors aim to elucidate the mechanisms underlying immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA), which occurs in approximately 6% of patients receiving ICI cancer therapy and resembles rheumatoid arthritis. They discuss the cellular characteristics of ICI-IA, including the role of specific T cell and macrophage populations, and suggest that understanding ICI-IA may provide insights into the biology of other inflammatory arthritis forms. The review highlights current knowledge and proposes future research directions in this area.

Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a long-term multicenter observational study

Mar 9, 2026

This study aimed to investigate the long-term effects of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) on bone mineral density (BMD) in patients with rheumatoid arthritis (RA). Despite improvements in clinical disease activity, the findings revealed that b/tsDMARDs did not prevent the progression of osteoporosis, as BMD decreased significantly in patients not receiving osteoporosis treatment, highlighting the need to address osteoporosis independently from RA management.